Ken Griffin Dyne Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 20,200 shares of DYN stock, worth $643,976. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,200
Previous 19,100
5.76%
Holding current value
$643,976
Previous $254,000
125.59%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding DYN
# of Institutions
176Shares Held
87.1MCall Options Held
130KPut Options Held
209K-
Atlas Venture Life Science Advisors, LLC8.02MShares$256 Million28.49% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$250 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$172 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$145 Million4.27% of portfolio
-
State Street Corp Boston, MA4.19MShares$134 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.65B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...